The Experts below are selected from a list of 89520 Experts worldwide ranked by ideXlab platform

Jesse Chung Sean Pang - One of the best experts on this subject based on the ideXlab platform.

  • Targeting of YAP1 by microRNA-15a and microRNA-16-1 exerts tumor suppressor function in gastric adenocarcinoma
    Molecular Cancer, 2015
    Co-Authors: Wei Kang, Li Zhang, Joanna H.m. Tong, Raymond W.m. Lung, Yujuan Dong, Junhong Zhao, Qiaoyi Liang, Yi Pan, Weiqin Yang, Jesse Chung Sean Pang
    Abstract:

    Background microRNAs (miRNAs) have been reported to play an important role in tumorigenesis. In this study, the role of miR-15a and miR-16-1 in gastric adenocarcinoma (GAC) was investigated.

  • targeting of yap1 by microRNA 15a and microRNA 16 1 exerts tumor suppressor function in gastric adenocarcinoma
    Molecular Cancer, 2015
    Co-Authors: Wei Kang, Li Zhang, Joanna H.m. Tong, Raymond W.m. Lung, Yujuan Dong, Junhong Zhao, Qiaoyi Liang, Yi Pan, Weiqin Yang, Jesse Chung Sean Pang
    Abstract:

    microRNAs (miRNAs) have been reported to play an important role in tumorigenesis. In this study, the role of miR-15a and miR-16-1 in gastric adenocarcinoma (GAC) was investigated. The expression of miR-15a and miR-16-1 in cell lines and primary tumors was examined by miRNA qRT-PCR. Proliferative assays, colony formation, cell invasion and migration, flow cytometry analysis and in vivo study were performed by ectopic expression of miR-15a and miR-16-1. The putative target genes of miR-15a and miR-16-1 were explored by TargetScan and further validated. We found that miR-15a and miR-16-1 were down-regulated in GAC cell lines and primary tumor samples compared with normal gastric epithelium. Functional study demonstrated that ectopic expression of miR-15a and miR-16-1 suppressed cell proliferation, monolayer colony formation, invasion and migration, and xenograft formation in vivo. In addition, miR-15a and miR-16-1 induced G0/G1 cell cycle arrest which was further confirmed by Western blot and qRT-PCR of related cell cycle regulators. YAP1 was confirmed to be a functional target of miR-15a and miR-16-1 in GAC. YAP1 re-expression partly abrogated the inhibitory effect of miR-15a and miR-16-1 in GAC cells. In clinical samples, YAP1 protein expression shows negative correlation with miR-15a and miR-16-1 expression. In conclusion, targeting YAP1 by tumor suppressor miRNA miR-15a and miR-16-1 plays inhibitory effect and this might have a therapeutic potential in GAC.

Rosa Vono - One of the best experts on this subject based on the ideXlab platform.

  • microRNA 15a and microRNA 16 impair human circulating proangiogenic cell functions and are increased in the proangiogenic cells and serum of patients with critical limb ischemia
    Circulation Research, 2013
    Co-Authors: Gaia Spinetti, Andrea Caporali, Orazio Fortunato, Saran Shantikumar, Micol Marchetti, Marco Meloni, Betty Descamps, Ilaria Floris, Elena Sangalli, Rosa Vono
    Abstract:

    Rationale:Circulating proangiogenic cells (PACs) support postischemic neovascularization. Cardiovascular disease and diabetes mellitus impair PAC regenerative capacities via molecular mechanisms th...

  • microRNA 15a and microRNA 16 impair human circulating proangiogenic cell functions and are increased in the proangiogenic cells and serum of patients with critical limb ischemia
    Circulation Research, 2013
    Co-Authors: Gaia Spinetti, Andrea Caporali, Orazio Fortunato, Saran Shantikumar, Micol Marchetti, Marco Meloni, Betty Descamps, Ilaria Floris, Elena Sangalli, Rosa Vono
    Abstract:

    Rationale:Circulating proangiogenic cells (PACs) support postischemic neovascularization. Cardiovascular disease and diabetes mellitus impair PAC regenerative capacities via molecular mechanisms that are not fully known. We hypothesize a role for microRNAs (miRs). Circulating miRs are currently investigated as potential diagnostic and prognostic biomarkers. Objective:The objectives were the following: (1) to profile miR expression in PACs from critical limb ischemia (CLI) patients; (2) to demonstrate that miR-15a and miR-16 regulate PAC functions; and (3) to characterize circulating miR-15a and miR-16 and to investigate their potential biomarker value. Methods and Results:Twenty-eight miRs potentially able to modulate angiogenesis were measured in PACs from CLI patients with and without diabetes mellitus and controls. miR-15a and miR-16 were further analyzed. CLI-PACs expressed higher level of mature miR-15a and miR-16 and of the primary transcript pri–miR-15a/16-1. miR-15a/16 overexpression impaired heal...

  • microRNA-15a and microRNA-16 Impair Human Circulating Pro-Angiogenic Cell (PAC) Functions and are Increased in the PACs and Serum of Patients with Critical Limb Ischemia
    Circulation Research, 2013
    Co-Authors: Gaia Spinetti, Andrea Caporali, Orazio Fortunato, Saran Shantikumar, Micol Marchetti, Marco Meloni, Betty Descamps, Ilaria Floris, Elena Sangalli, Rosa Vono
    Abstract:

    Rationale: Circulating Proangiogenic Cells (PACs) support post-ischemic neovascularization. Cardiovascular disease and diabetes impair PAC regenerative capacities via not fully known molecular mechanisms. We hypothesize a role for microRNAs (miRs). Circulating miRs are currently investigated as potential diagnostic and prognostic biomarkers. Objective: 1) To profile miR expression in PACs from critical limb ischemia (CLI) patients; 2) To demonstrate that miR-15a and miR-16 regulate PAC functions; 3) To characterize circulating miR-15a and miR-16 and to investigate their potential biomarker value. Methods and Results: Twenty-eight miRs potentially able to modulate angiogenesis were measured in PACs from CLI patients with/out diabetes and controls. miR-15a and miR-16 were further analyzed. CLI-PACs expressed higher level of mature miR-15a and miR-16 and of the primary transcript primiR-15a/16-1. miR-15a/-16 overexpression impaired healthy PACs survival and migration. Conversely, miR-15a/-16 inhibition improved CLI-PAC defective migration. VEGF-A and AKT-3 were validated as direct targets of the two miRs and their protein levels were reduced in miR-15a/-16-overexpressing healthy PACs and in CLI-PACs. Transplantation of healthy PACs ex-vivo engineered with anti-miR-15a/-16 improved post-ischemic blood flow recovery and muscular arteriole density in immunodeficient mice. miR-15a and miR-16 were present in human blood, including conjugated to Argonaute-2 and in exosomes. Both miRs were increased in the serum of CLI patients and positively correlated with amputation after restenosis at 12 months post-revascularization of CLI-T2D patients. Serum miR-15a additionally correlated with restenosis at follow-up. Conclusions: 1) Ex-vivo miR-15a/16 inhibition enhances PAC therapeutic potential; 2) circulating miR-15a deserves further investigation as prognostic biomarker in CLI patients undergoing revascularization.

Andrea Caporali - One of the best experts on this subject based on the ideXlab platform.

  • microRNA 15a and microRNA 16 impair human circulating proangiogenic cell functions and are increased in the proangiogenic cells and serum of patients with critical limb ischemia
    Circulation Research, 2013
    Co-Authors: Gaia Spinetti, Andrea Caporali, Orazio Fortunato, Saran Shantikumar, Micol Marchetti, Marco Meloni, Betty Descamps, Ilaria Floris, Elena Sangalli, Rosa Vono
    Abstract:

    Rationale:Circulating proangiogenic cells (PACs) support postischemic neovascularization. Cardiovascular disease and diabetes mellitus impair PAC regenerative capacities via molecular mechanisms that are not fully known. We hypothesize a role for microRNAs (miRs). Circulating miRs are currently investigated as potential diagnostic and prognostic biomarkers. Objective:The objectives were the following: (1) to profile miR expression in PACs from critical limb ischemia (CLI) patients; (2) to demonstrate that miR-15a and miR-16 regulate PAC functions; and (3) to characterize circulating miR-15a and miR-16 and to investigate their potential biomarker value. Methods and Results:Twenty-eight miRs potentially able to modulate angiogenesis were measured in PACs from CLI patients with and without diabetes mellitus and controls. miR-15a and miR-16 were further analyzed. CLI-PACs expressed higher level of mature miR-15a and miR-16 and of the primary transcript pri–miR-15a/16-1. miR-15a/16 overexpression impaired heal...

  • microRNA 15a and microRNA 16 impair human circulating proangiogenic cell functions and are increased in the proangiogenic cells and serum of patients with critical limb ischemia
    Circulation Research, 2013
    Co-Authors: Gaia Spinetti, Andrea Caporali, Orazio Fortunato, Saran Shantikumar, Micol Marchetti, Marco Meloni, Betty Descamps, Ilaria Floris, Elena Sangalli, Rosa Vono
    Abstract:

    Rationale:Circulating proangiogenic cells (PACs) support postischemic neovascularization. Cardiovascular disease and diabetes mellitus impair PAC regenerative capacities via molecular mechanisms th...

  • microRNA-15a and microRNA-16 Impair Human Circulating Pro-Angiogenic Cell (PAC) Functions and are Increased in the PACs and Serum of Patients with Critical Limb Ischemia
    Circulation Research, 2013
    Co-Authors: Gaia Spinetti, Andrea Caporali, Orazio Fortunato, Saran Shantikumar, Micol Marchetti, Marco Meloni, Betty Descamps, Ilaria Floris, Elena Sangalli, Rosa Vono
    Abstract:

    Rationale: Circulating Proangiogenic Cells (PACs) support post-ischemic neovascularization. Cardiovascular disease and diabetes impair PAC regenerative capacities via not fully known molecular mechanisms. We hypothesize a role for microRNAs (miRs). Circulating miRs are currently investigated as potential diagnostic and prognostic biomarkers. Objective: 1) To profile miR expression in PACs from critical limb ischemia (CLI) patients; 2) To demonstrate that miR-15a and miR-16 regulate PAC functions; 3) To characterize circulating miR-15a and miR-16 and to investigate their potential biomarker value. Methods and Results: Twenty-eight miRs potentially able to modulate angiogenesis were measured in PACs from CLI patients with/out diabetes and controls. miR-15a and miR-16 were further analyzed. CLI-PACs expressed higher level of mature miR-15a and miR-16 and of the primary transcript primiR-15a/16-1. miR-15a/-16 overexpression impaired healthy PACs survival and migration. Conversely, miR-15a/-16 inhibition improved CLI-PAC defective migration. VEGF-A and AKT-3 were validated as direct targets of the two miRs and their protein levels were reduced in miR-15a/-16-overexpressing healthy PACs and in CLI-PACs. Transplantation of healthy PACs ex-vivo engineered with anti-miR-15a/-16 improved post-ischemic blood flow recovery and muscular arteriole density in immunodeficient mice. miR-15a and miR-16 were present in human blood, including conjugated to Argonaute-2 and in exosomes. Both miRs were increased in the serum of CLI patients and positively correlated with amputation after restenosis at 12 months post-revascularization of CLI-T2D patients. Serum miR-15a additionally correlated with restenosis at follow-up. Conclusions: 1) Ex-vivo miR-15a/16 inhibition enhances PAC therapeutic potential; 2) circulating miR-15a deserves further investigation as prognostic biomarker in CLI patients undergoing revascularization.

  • microRNA 503 and the extended microRNA 16 family in angiogenesis
    Trends in Cardiovascular Medicine, 2011
    Co-Authors: Andrea Caporali, Costanza Emanueli
    Abstract:

    microRNAs (miRs) are post-transcriptional inhibitory regulators of gene expression acting by direct binding to complementary messenger RNA (mRNA) transcripts. Recent studies have demonstrated that miRs are crucial determinants of endothelial cell behavior and angiogenesis. We have provided evidence of the prominent role of miR-503 in impairment of postischemic reparative angiogenesis in the setting of diabetes. Because miR-503 belongs to the miR-16 extended family of miRs, in this review, we describe the cardiovascular functions of miR-503 and other members of the miR-16 family and their impact on angiogenesis.

Wei Kang - One of the best experts on this subject based on the ideXlab platform.

  • Targeting of YAP1 by microRNA-15a and microRNA-16-1 exerts tumor suppressor function in gastric adenocarcinoma
    Molecular Cancer, 2015
    Co-Authors: Wei Kang, Li Zhang, Joanna H.m. Tong, Raymond W.m. Lung, Yujuan Dong, Junhong Zhao, Qiaoyi Liang, Yi Pan, Weiqin Yang, Jesse Chung Sean Pang
    Abstract:

    Background microRNAs (miRNAs) have been reported to play an important role in tumorigenesis. In this study, the role of miR-15a and miR-16-1 in gastric adenocarcinoma (GAC) was investigated.

  • targeting of yap1 by microRNA 15a and microRNA 16 1 exerts tumor suppressor function in gastric adenocarcinoma
    Molecular Cancer, 2015
    Co-Authors: Wei Kang, Li Zhang, Joanna H.m. Tong, Raymond W.m. Lung, Yujuan Dong, Junhong Zhao, Qiaoyi Liang, Yi Pan, Weiqin Yang, Jesse Chung Sean Pang
    Abstract:

    microRNAs (miRNAs) have been reported to play an important role in tumorigenesis. In this study, the role of miR-15a and miR-16-1 in gastric adenocarcinoma (GAC) was investigated. The expression of miR-15a and miR-16-1 in cell lines and primary tumors was examined by miRNA qRT-PCR. Proliferative assays, colony formation, cell invasion and migration, flow cytometry analysis and in vivo study were performed by ectopic expression of miR-15a and miR-16-1. The putative target genes of miR-15a and miR-16-1 were explored by TargetScan and further validated. We found that miR-15a and miR-16-1 were down-regulated in GAC cell lines and primary tumor samples compared with normal gastric epithelium. Functional study demonstrated that ectopic expression of miR-15a and miR-16-1 suppressed cell proliferation, monolayer colony formation, invasion and migration, and xenograft formation in vivo. In addition, miR-15a and miR-16-1 induced G0/G1 cell cycle arrest which was further confirmed by Western blot and qRT-PCR of related cell cycle regulators. YAP1 was confirmed to be a functional target of miR-15a and miR-16-1 in GAC. YAP1 re-expression partly abrogated the inhibitory effect of miR-15a and miR-16-1 in GAC cells. In clinical samples, YAP1 protein expression shows negative correlation with miR-15a and miR-16-1 expression. In conclusion, targeting YAP1 by tumor suppressor miRNA miR-15a and miR-16-1 plays inhibitory effect and this might have a therapeutic potential in GAC.

Gaia Spinetti - One of the best experts on this subject based on the ideXlab platform.

  • microRNA 15a and microRNA 16 impair human circulating proangiogenic cell functions and are increased in the proangiogenic cells and serum of patients with critical limb ischemia
    Circulation Research, 2013
    Co-Authors: Gaia Spinetti, Andrea Caporali, Orazio Fortunato, Saran Shantikumar, Micol Marchetti, Marco Meloni, Betty Descamps, Ilaria Floris, Elena Sangalli, Rosa Vono
    Abstract:

    Rationale:Circulating proangiogenic cells (PACs) support postischemic neovascularization. Cardiovascular disease and diabetes mellitus impair PAC regenerative capacities via molecular mechanisms th...

  • microRNA 15a and microRNA 16 impair human circulating proangiogenic cell functions and are increased in the proangiogenic cells and serum of patients with critical limb ischemia
    Circulation Research, 2013
    Co-Authors: Gaia Spinetti, Andrea Caporali, Orazio Fortunato, Saran Shantikumar, Micol Marchetti, Marco Meloni, Betty Descamps, Ilaria Floris, Elena Sangalli, Rosa Vono
    Abstract:

    Rationale:Circulating proangiogenic cells (PACs) support postischemic neovascularization. Cardiovascular disease and diabetes mellitus impair PAC regenerative capacities via molecular mechanisms that are not fully known. We hypothesize a role for microRNAs (miRs). Circulating miRs are currently investigated as potential diagnostic and prognostic biomarkers. Objective:The objectives were the following: (1) to profile miR expression in PACs from critical limb ischemia (CLI) patients; (2) to demonstrate that miR-15a and miR-16 regulate PAC functions; and (3) to characterize circulating miR-15a and miR-16 and to investigate their potential biomarker value. Methods and Results:Twenty-eight miRs potentially able to modulate angiogenesis were measured in PACs from CLI patients with and without diabetes mellitus and controls. miR-15a and miR-16 were further analyzed. CLI-PACs expressed higher level of mature miR-15a and miR-16 and of the primary transcript pri–miR-15a/16-1. miR-15a/16 overexpression impaired heal...

  • microRNA-15a and microRNA-16 Impair Human Circulating Pro-Angiogenic Cell (PAC) Functions and are Increased in the PACs and Serum of Patients with Critical Limb Ischemia
    Circulation Research, 2013
    Co-Authors: Gaia Spinetti, Andrea Caporali, Orazio Fortunato, Saran Shantikumar, Micol Marchetti, Marco Meloni, Betty Descamps, Ilaria Floris, Elena Sangalli, Rosa Vono
    Abstract:

    Rationale: Circulating Proangiogenic Cells (PACs) support post-ischemic neovascularization. Cardiovascular disease and diabetes impair PAC regenerative capacities via not fully known molecular mechanisms. We hypothesize a role for microRNAs (miRs). Circulating miRs are currently investigated as potential diagnostic and prognostic biomarkers. Objective: 1) To profile miR expression in PACs from critical limb ischemia (CLI) patients; 2) To demonstrate that miR-15a and miR-16 regulate PAC functions; 3) To characterize circulating miR-15a and miR-16 and to investigate their potential biomarker value. Methods and Results: Twenty-eight miRs potentially able to modulate angiogenesis were measured in PACs from CLI patients with/out diabetes and controls. miR-15a and miR-16 were further analyzed. CLI-PACs expressed higher level of mature miR-15a and miR-16 and of the primary transcript primiR-15a/16-1. miR-15a/-16 overexpression impaired healthy PACs survival and migration. Conversely, miR-15a/-16 inhibition improved CLI-PAC defective migration. VEGF-A and AKT-3 were validated as direct targets of the two miRs and their protein levels were reduced in miR-15a/-16-overexpressing healthy PACs and in CLI-PACs. Transplantation of healthy PACs ex-vivo engineered with anti-miR-15a/-16 improved post-ischemic blood flow recovery and muscular arteriole density in immunodeficient mice. miR-15a and miR-16 were present in human blood, including conjugated to Argonaute-2 and in exosomes. Both miRs were increased in the serum of CLI patients and positively correlated with amputation after restenosis at 12 months post-revascularization of CLI-T2D patients. Serum miR-15a additionally correlated with restenosis at follow-up. Conclusions: 1) Ex-vivo miR-15a/16 inhibition enhances PAC therapeutic potential; 2) circulating miR-15a deserves further investigation as prognostic biomarker in CLI patients undergoing revascularization.